Novel Nitrile Peptidomimetics for Treating COVID-19
C. S. Brian Chia
Abstract
COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure-activity relationship of key inhibitors described in the patent WO 2021/250648 A1.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)PeptidomimeticSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyAuthorizationInfectious disease (medical specialty)MedicineProteaseDiseaseBiologyInternal medicineComputer scienceComputer securityBiochemistryEnzymeOutbreakPeptideAntimicrobial Peptides and ActivitiesAdvanced biosensing and bioanalysis techniquesPeptidase Inhibition and Analysis